BioChromix AB

The Challenge

Alzheimer's disease (AD) affects nearly 1% of the world population. It is a progressive, degenerative, irreversible disease, and the most common form of dementia. The only reliable diagnosis of Alzheimer's disease that we have today is post mortem identification of the disease in the brain. There are no cures for AD at present. To achieve an effective treatment of the disease it is necessary to start treatment early, before the first symptom, memory disturbance, occurs. Therefore it is essential to develop a reliable test that can identify those at risk of developing the disease. Today there is no such test.

BioChromix’s Solution

BioChromix has developed a sensitive method that can detect Aß oligomers in biological samples such as cerebrospinal fluid. The formation of these small peptide aggregates, Aß oligomers, is associated with AD. Thus, it would be possible to diagnose the disease by measuring the amount of oligomers in cerebrospinal fluid, for example. To do this you need a sensitive and reliable method, which is currently not available. BioChromix’s test would also be very helpful for monitoring the effectiveness of different treatments and the development of new drugs for AD. There is a great commercial need for BioChromix’ unique products. Development is focused on R&D assays, in vitro diagnostics and in vivo imaging of AD.

The Company's patented methods are based on the novel luminescent conjugated polymer (LCP) molecules.

Competitive Advantages

By combining the LCP technology with traditional standard high-sensitivity laboratory equipment BioChromix aims to provide unique methods and products that enable analysis of the pathological events leading to AD with extremely high accuracy. Today there are no efficient methods approved to measure levels of soluble Aß oligomers for the development of next generation drugs for AD.  Drugs targeting the Aß directly or modifying the Aß fibrillation, like Beta secretase inhibitors or Aß aggregation inhibitors, are the preferred approach currently being taken by big pharma. BioChromix see great value in being able to offer a  unique method to measure Aß oligomers to these pharmaceutical companies.